Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Topix Pharmaceuticals, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 4 examiners and 3 art units, indicating a small portfolio with limited art-unit dispersion and no repeated examiner assignment in the listed data.
BARBER, KIMBERLY is the busiest examiner, with 1 pending matter. The portfolio is compact enough for direct matter-by-matter review, while the presence of 3 art units still warrants attention to differences in examination practice across the biotechnology and pharmaceutical cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARBER, KIMBERLY | 1 | 71.1% | +21.4% |
| CRAIGO, WILLIAM A | 1 | 49.0% | +38.0% |
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18796710 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | CRAIGO, WILLIAM A | — |
| 18038576 | SCAR TREATMENT COMPOSITION | DAVIS, RUTH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18751708 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | CHANG, KYUNG SOOK | 53d overdue |
| 19263721 | BOTANICAL CALMING COMPOSITION | BARBER, KIMBERLY | — |
| 18796710 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | CRAIGO, WILLIAM A | — |
| 18038576 | SCAR TREATMENT COMPOSITION | DAVIS, RUTH A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1613 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19263721 | BOTANICAL CALMING COMPOSITION | BARBER, KIMBERLY | 1615 | §103 | Non-Final OA | — | Pending | Jul 09, 2025 |
| 18796710 | METHODS, COMPOSITIONS, AND DELIVERY SYSTEMS FOR THERAPEUTIC SKIN TREATMENTS | CRAIGO, WILLIAM A | 1615 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18751708 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | CHANG, KYUNG SOOK | 1613 | §112 | Non-Final OA | 53d overdue | Pending | Jun 24, 2024 |
| 18038576 | SCAR TREATMENT COMPOSITION | DAVIS, RUTH A | 1699 | §102§112 | Non-Final OA | — | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTopix Pharmaceuticals, Inc. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.
Kimberly Barber has the most, with 1 of Topix Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.